Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Iacono

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
Emerging Infectious Diseases|March 21, 2007
Clusters of hantavirus infection, southern ArgentinaMaria E Lázaro, Gustavo E Cantoni, Liliana M Calanni, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 3, 2006
Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]G La Rana, R Russo, P Campolongo, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 1, 1997
Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipientsR J Keenan, A Iacono, J H Dauber, et al.
Human Immunology|February 13, 2001
Soluble donor HLA class I and beta 2m-free heavy chain in serum of lung transplant recipients: steady-state levels and increases in patients with recurrent CMV infection, acute rejection episodes, and poor outcomeL D DeVito-Haynes, E Jankowska-Gan, K C Meyer, et al.
Transplant Immunology|April 9, 2005
The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patientsH X Zheng, A Zeevi, K McCurry, et al.
Transplantation|July 27, 1997
Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporineA Iacono, J Dauber, R Keenan, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2013
[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]V Saglimbene, D D'Alonzo, M Ruospo, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Emerging Infectious Diseases|March 21, 2007
Clusters of hantavirus infection, southern ArgentinaMaria E Lázaro, Gustavo E Cantoni, Liliana M Calanni, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 3, 2006
Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]G La Rana, R Russo, P Campolongo, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 1, 1997
Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipientsR J Keenan, A Iacono, J H Dauber, et al.
Human Immunology|February 13, 2001
Soluble donor HLA class I and beta 2m-free heavy chain in serum of lung transplant recipients: steady-state levels and increases in patients with recurrent CMV infection, acute rejection episodes, and poor outcomeL D DeVito-Haynes, E Jankowska-Gan, K C Meyer, et al.
Transplant Immunology|April 9, 2005
The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patientsH X Zheng, A Zeevi, K McCurry, et al.
Transplantation|July 27, 1997
Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporineA Iacono, J Dauber, R Keenan, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2013
[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]V Saglimbene, D D'Alonzo, M Ruospo, et al.
Pageof 13